Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Accumulated Expenses (2016)

Viridian Therapeutics, Inc.\DE has reported Other Accumulated Expenses over the past 3 years, most recently at $148000.0 for Q4 2016.

  • Quarterly results put Other Accumulated Expenses at $148000.0 for Q4 2016, up 76.19% from a year ago — trailing twelve months through Dec 2016 was $148000.0 (up 76.19% YoY), and the annual figure for FY2016 was $148000.0, up 76.19%.
  • Other Accumulated Expenses for Q4 2016 was $148000.0 at Viridian Therapeutics, Inc.\DE, up from $48000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for VRDN hit a ceiling of $148000.0 in Q4 2016 and a floor of $39000.0 in Q1 2016.
  • Median Other Accumulated Expenses over the past 3 years was $83000.0 (2016), compared with a mean of $79832.6.
  • Peak annual rise in Other Accumulated Expenses hit 97.62% in 2016, while the deepest fall reached 58.51% in 2016.
  • Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses stood at $62000.0 in 2014, then surged by 35.48% to $84000.0 in 2015, then soared by 76.19% to $148000.0 in 2016.
  • The last three reported values for Other Accumulated Expenses were $148000.0 (Q4 2016), $48000.0 (Q3 2016), and $83000.0 (Q2 2016) per Business Quant data.